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Introduction
Heart failure is increasing in prevalence and is a debilitating dis-
ease with high rates of mortality and morbidity [1]. Cardiac hyper-
trophy is a common precursor to many forms of heart failure,
whose molecular and cellular determinants remain largely
unknown [2]. After a period of compensatory adaptation, hyper-
trophy is associated with functional and histological deterioration
of the myocardium, fibrosis, inflammation and altered cardiac
gene expression [2, 3].
Studies have demonstrated that adenovirus E1A protein both
activates and represses gene expression to promote DNA synthe-
sis and cellular proliferation [4]. In many cell types, the adenovirus
E1A protein dramatically alters the transcriptional program of the
host cell to stimulate cell division and inhibit differentiation [5].
Investigations into the mechanisms by which E1A activates and
represses expression of particular genes have revealed that E1A
interacts with several transcriptional regulators of cell prolifera-
tion, including the coactivators p300 and CBP, which play impor-
tant role in cardiac hypertrophy and heart failure [6, 7]. Therefore,
E1A is an attractive target for therapeutic intervention to treat or
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Cellular repressor of E1A-stimulated genes (CREG) is a secreted glycoprotein of 220 amino acids. It has been proposed that CREG acts
as a ligand that enhances differentiation and/or reduces cell proliferation. CREG has been shown previously to attenuate cardiac hyper-
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of CREG in the murine heart would protect against cardiac hypertrophy and fibrosis in vivo. The effects of constitutive human CREG expres-
sion on cardiac hypertrophy were investigated using both in vitro and in vivo models. Cardiac hypertrophy was produced by aortic band-
ing and infusion of angiotensin II in CREG transgenic mice and control animals. The extent of cardiac hypertrophy was quantitated by  
two-dimensional and M-mode echocardiography as well as by molecular and pathological analyses of heart samples. Constitutive over-
expression of human CREG in the murine heart attenuated the hypertrophic response, markedly reduced inflammation. Cardiac function
was also preserved in hearts with increased CREG levels in response to hypertrophic stimuli. These beneficial effects were associated with
attenuation of the mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase 1 (MEK-ERK1)/2-dependent signalling
cascade. In addition, CREG expression blocked fibrosis and collagen synthesis through blocking MEK-ERK1/2-dependent Smad 2/3 acti-
vation in vitro and in vivo. Therefore, the expression of CREG improves cardiac functions and inhibits cardiac hypertrophy, inflammation
and fibrosis through blocking MEK-ERK1/2-dependent signalling.
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prevent cardiac hypertrophy and heart failure. The cellular repres-
sor of E1A-stimulated genes (CREG) is a secreted glycoprotein
that has been shown to antagonize transcription activation and
cellular transformation induced by the adenovirus E1A oncopro-
tein [8]. Recent studies showed that CREG transferring to the
injured artery inhibited SMC dedifferentiation and proliferation,
and reduced neointimal hyperplasia [9, 10]. Xu and colleagues
[11] reported that CREG expression is decreased during biome-
chanical stress in the heart and functions to attenuate cardiac
hypertrophy in vitro. Despite the potentially significant roles of
CREG in attenuating hypertrophic signalling, it has remained
unclear whether CREG could regulate cardiac hypertrophy in vivo,
and whether targeted myocardial overexpression of CREG is car-
dio-protective. Thus in the present study, our aimed to investigate
the role of CREG in cardiac hypertrophy mediated by pressure
overload and Angiogensin II (Ang II) and to clarify the related
molecular mechanisms.
Methods and materials
Materials
Antibodies for the mitogen-activated protein kinases (MAPKs) and Smads
pathways were purchased from Cell Signaling Technology (Danvers, MA,
USA). The anti-CREG (reactive with mouse or human) antibody was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). [3H]-
Leucine and [3H]-proline were purchased from Amersham. NF-B-luc,
CTGF- and COL1A2-luc report constructs were described previously [12].
The bicinchoninic acid (BCA) protein assay kit was purchased from Pierce
(Rockford, IL, USA). All other antibodies were purchased from Santa Cruz
Biotechnology. Transforming growth factor-1 (TGF-1) was purchased
from R&D Systems (Minneapolis, MN, USA). Foetal calf serum (FCS) was
obtained from Hyclone (Logan, UT, USA). Cell culture reagents and all
other reagents were obtained from Sigma (Oakville, ON, Canada).
Animals and animal models
All protocols were approved by the Animal Care and Use Committee of the
hospital. Human CREG cDNA construct containing full-length human CREG
cDNA (kindly provide by Dr Grace Gill, School of Medicine, Tufts
University) was cloned downstream of the cardiac -myosin heavy chain
(-MHC) promoter. Transgenic (TG) mice were produced by microinjection
of the -MHC-CREG construct into fertilized mouse embryos [friend virus
B strain (FVB) background]. Four independent transgenic lines were estab-
lished and studied. TG mice were identified by PCR analysis of tail genomic
DNA. Gene expression levels and cardiac function were analysed in pairs
of -MHC-CREG (TG) and littermate wild-type (WT) male mice ranging in
age from 8 to 10 weeks. Aortic banding (AB) was performed as described
previously [12]. Doppler analysis was performed to ensure the adequate
constriction of the aorta. To confirm the role of CREG in cardiac hypertro-
phy, the experiments were repeated in an Ang II Infusion model. Ang II (1.4
mg/kg/day and dissolved in 0.9% NaCl) was subcutaneously infused for 4
weeks using an osmotic minipump (Alzet model 2004; Alza Corp, Vacaville,
CA, USA) implanted in each mouse. Saline-infused animals served as infu-
sion controls and were subjected to the same procedures as the experi-
mental animals except for Ang II infusion. The internal diameter and wall
thickness of the left ventricle were assessed by echocardiography after sur-
gery or infusion. Hearts and lungs of the killed mice were dissected and
weighed to compare heart weight/body weight (HW/BW, mg/g) and lung
weight/body weight (LW/BW, mg/g) ratios in different groups.
Echocardiography and blood pressure
Echocardiography was performed by SONOS 5500 ultrasound (Philips
Electronics, Amsterdam, Netherlands) with a 15-MHz linear array ultra-
sound transducer. The left ventricle was assessed in both parasternal long-
and short-axis views at a frame rate of 120 Hz. End-systole or end-diastole
was defined as the phase in which the smallest or largest area of left ven-
tricle, respectively, was obtained. For measurements of blood pressure and
heart rate, a microtip catheter transducer (SPR-839, Millar Instruments,
Houston, TX, USA) was inserted into the right carotid artery and advanced
into the left ventricle. After stabilization for 15 min., the pressure signals
and heart rate were recorded continuously with an ARIA pressure–volume
conductance system as described previously [12].
Quantitative real-time RT-PCR and Western blotting
Real-time PCR was used to detect the mRNA expression levels of hyper-
trophic, fibrotic and inflammatory markers. Total RNA was extracted from
frozen, pulverized mouse cardiac tissue using TRIzol (Invitrogen, Carlsbad,
CA, USA) and synthesized cDNA using oligo (dT) primers (listed in Table S1)
with the Advantage RT-for-PCR kit (BD Biosciences, San Jose, CA, USA).
We quantitated PCR amplifications using SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, CA, USA) and normalized results against
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) gene expression.
For Western blot, cardiac tissue and cultured cardiac myocytes or fibrob-
lasts were lysed in RIPA lysis buffer. Fifty  micrograms of cell lysate was
used for SDS-PAGE, and proteins were then transferred to an Immobilon-
P membrane (Millipore, Billerica, MA, USA). Specific protein expression
levels were normalized by either the GAPDH protein for total cell lysate and
cytosolic proteins, or the Lamin-B1 protein for nuclear proteins on the same
nitrocellulose membrane.
Electrophoretic mobility shift assays (EMSA) 
and histological analysis
For EMSA, nuclear proteins were isolated as described previously [12, 13].
EMSA was performed according to the manufacturer’s instructions (Gel
Shift Assay System E3300, Promega, Madison, WI, USA). Synthetic, dou-
ble-strand oligonucleotides containing NF-B binding domain were
labelled with [-32P] ATP using T4 polynucleotide kinase and separated
from unincorporated [-32P] ATP by gel filtration using a Nick column
(Pharmacia, North Peapack, NJ, USA). For histological analysis, hearts
were excised, washed with saline solution, and fixed in 10% formalin.
Hearts were cut transversely close to the apex to visualize the left and right
ventricle. Several sections of heart (4–5-m thick) were prepared and
stained with haematoxylin and eosin for histopathology or Picrosirius red
(PSR) for collagen deposition and then visualized by light microscopy. For
Fig. 1 Characterization of human CREG transgenic (TG) mice. (A) Representative Western blot of human CREG protein from different tissue of TG mice
as indicated. (B) Representative Western blots of human CREG protein in the heart tissue from 4 lines of both TG and WT mice. (C) Representative
Western blots of TG CREG and endogenous CREG protein levels in the heart from TG mice. (D) Representative Western blots of mouse and human
CREG protein in the heart tissue from TG mice after aortic banding at time-points indicated.
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myocyte cross-sectional area, sections were stained for membranes with
FITC-conjugated wheat germ agglutinin (WGA, Invitrogen Corp) and for
nuclei with DAPI. Single myocyte was measured with an image quantitative
digital analysis system (Image-Pro 4.5, Media Cybernetics, Silver Spring,
MD, USA). The outline of 250 myocytes was traced in each section.
Recombinant adenoviral vectors, and cultured
neonatal rat cardiac myocytes and fibroblasts
We used replication-defective adenoviral vectors encoding for the entire
coding region of human CREG gene under the control of the cytomegalovirus
promoter. The same adenoviral vector encoding for the GFP gene (AdEasy
XL adenoviral Vector system, Strategene, La Jolla, CA, USA) was used as
control. We ordered three independent rat shCREG constructs from
SuperArray (Cat. no. KR43991G) and then generated three Ad-shCREG
adenovirus, and chose the one that led to a significant decrease in CREG
levels for further experiments. Ad-shRNA was used as control. Cardiac
myocytes were infected with Ad-CREG and Ad-GFP as well as Ad-shCREG
and Ad-shRNA at a multiplicity of infection (MOI) of 100, resulting in 95–
100% of cells expressing the transgenes without toxicity. Primary cultures
of cardiac myocytes were prepared as described previously [12].
Cardiomyocytes isolated from the hearts of 1- to 2-day old Sprague-
Dawley rats (Charles River Laboratories, Senneville, Canada) were seeded
at a density of 1  106/well onto six-well culture plates in plating medium
consisting of F10 medium supplemented with 10% FCS and
penicillin/streptomycin. After 48 hrs, the culture medium was replaced with
F10 medium containing 0.1% FCS and BrdU (0.1 mM). Cultures of neona-
tal rat cardiac fibroblasts were prepared as described previously [12]. All
experiments were performed on cells from the first or second passages
which were placed in Dulbecco’s modified eagle medium (DMEM) medium
containing 0.1% FCS for 24 hrs before the experiment. The purity of car-
diac fibroblasts in these cultures was greater than 95% as determined by
positive staining for vimentin and negative staining for smooth muscle
actin and von Willebrand factor. For the cell infection, 1  106/well cardiac
myocytes or cardiac fibroblasts were cultured in six-well plates and
exposed to 2  108 pfu each of virus in 1 ml of serum-free medium for 
24 hrs. The cells were then washed and incubated in serum-containing
medium for 24 hrs.
Collagen synthesis assay and reporter assays
Collagen synthesis was evaluated by measuring 3H-proline incorpora-
tion as described previously [12]. Briefly, cardiac fibroblasts were
infected with different adenoviruses and then made quiescent by cul-
tured in 0.1% FCS DMEM for 24 hrs, and subsequently incubated with
TGF-1 and 5 Ci/ml 3H-proline for the indicated time. Cells were
washed with PBS twice, treated with ice-cold 5% trichloroacetic acid for
1 hr, and washed twice with distilled water. Cells were then lysed with 
1 N NaOH solution and counted in a liquid scintillation counter. The count
representing the amount of newly synthesized collagen was normalized
to the cell number. For reporter analysis, cardiac myocytes or cardiac
fibroblasts were seeded in triplicate in six-well plates. Cells were trans-
fected with 0.5 g of luciferase reporter constructs, and internal control
plasmid DNA using 10 l of LipofectAMINE reagent (Invitrogen),
according to the manufacturer’s instructions. After 6 hrs of exposure to the
DNA-LipofectAMINE complex, cells were cultured in medium containing
J. Cell. Mol. Med. Vol 13, No 7, 2009
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10% serum for 24 hrs and then incubated with serum-free medium for
12 hrs. Cells were infected with different adenoviral for 24 hrs and then
treated with Ang II for cardiac myocytes or TGF-1 for fibroblasts. Cells
were harvested using passive lysis buffer (Promega) according to the
manufacturer’s protocol. The luciferase activity was normalized by con-
trol plasmid. All experiments were done in triplicate and repeated 
at least three times.
Statistical analysis
All observers in this study were blinded to the actual conditions of the
experiment to minimize observer bias. Results were expressed as mean
 S.E.M. Differences among groups were tested by one-way ANOVA.
Comparisons between two groups were performed by unpaired Student’s
t-test. A value of P 	 0.05 was considered to be  significantly different.
Results
Generation of mice with cardiac-specific
 overexpression of CREG
To determine the role of CREG on cardiac hypertrophy, we
 generated TG mice with full-length human CREG cDNA under the
control of the -MHC promoter. Four lines of TG mice were
 confirmed by PCR. These lines were born in a normal Mendelian
distribution, thus excluding lethal developmental abnormalities.
They also exhibited normal reproductive rate and gender distribu-
tions and did not demonstrate any difference in longevity over 
56 weeks. All experiments were performed on male mice of 
8–10-weeks old. We analysed CREG protein levels in various
Table 1 Echocardiographic data showed the effects of CREG on cardiac hypertrophy induced by aortic banding model
Parameter WT-sham mice TG-sham mice WT-AB mice TG-AB mice
Number n 
 11 n 
 12 n 
 9 n 
 8
BW, g 25.7  1.5 25.5  2.2 26.8  1.6 26.0  1.2
HW/BW 4.54  0.12 4.47  0.07 7.19  0.11* 5.22  0.09*§
LW/BW 5.33  0.07 5.21  0.12 8.13  0.16* 5.78  0.14§
CSA 258  29.7 263  30.3 442  31.2* 295  22§
SBP, mmHg 115.3  4.2 117.8  3.2 152.0  4.9* 145.0  4.1*
HR, beats/min. 465  21 457  26 473  25 466  29
PWT(mm) 1.22  0.04 1.25  0.03 3.24  0. 02* 1.75  0.03§
LVEDD (mm) 3.63  0.04 3.72  0.05 5.78  0.04* 4.11  0.02§
LVESD (mm) 2.40  0.03 2.38  0.03 3.52  0.04* 2.53  0.04§
IVSd (mm) 0.62  0.02 0.62  0.03 1.65  0.03* 0.91  0.02§
LVPWd (mm) 0.65  0.02 0.66  0.02 1.29  0.04* 0.86  0.02§
FS (%) 53.7  2.2 55.5  4.1 26.3  2.9* 44.2  1.2*§
EF (%) 60.2  3.6 58.7  4.2 30.5  3.4* 47.5  3.1*§
LVEDP (mm Hg) 9.8  0.9 9.6  1.1 17.9  1.3* 12.5  1.5§
Left ventricular dP/dTmax (mm Hg/s) 8813.5  519.5 8877.3  544.1 7003.7  341.9* 8348.7  406.8§
Left ventricular dP/dTmin (mm Hg/s) 7783.5  581.2 7822.5  500.6 6162.8  322.3* 7481.8  452.7§
*P 	 0.01 was obtained for the WT-sham values; §P 	 0.01 was obtained for the WT-AB values after AB.
SBP 
 systolic blood pressure; HR 
 heart rate; BW 
 body weight; HW 
 heart weight; CSA 
 cardiomyocyte cross-sectional area; PWT 

posterior wall thickness; LVEDD 
 left ventricular end-diastolic diameter; LVESD 
 left ventricular end-systolic diameter; IVSd 
 left ventricular
septum, diastolic; LVPWd 
 left ventricular posterior wall, diastolic. FS 
 fractional shortening; EF 
 ejection fraction; LVEDP 
 left ventricular
end-diastolic pressure; All values are mean  S.E.M.
Fig. 2 The effects of CREG on cardiac hypertrophy in vivo. (A and B)
Gross hearts of sham and AB mice at 8 weeks after surgery or saline- or
Ang II-infused mice at 4weeks of infusion. (C and D) Haematoxylin and
eosin and wheat germ agglutinin (WGA) staining of sham and AB mice at
8 weeks after surgery. (E and F) Haematoxylin and eosin and WGA stain-
ing of 4 weeks of saline- and Ang II-infused mice. (G and H) Analysis of
hypertrophic markers. Total RNA was isolated from hearts of mice of the
indicated groups, and expression of transcripts for ANP, BNP, Myh-7
and Acta1 induced by AB or Ang II infusion were determined by real-time
PCR analysis. Data represent typical results of three to four different
experiments as mean  S.E.M. (n 
 4 to 6 mice/per group). 
*P 	 0.01 was obtained for the WT/sham or WT/saline values.
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 tissues by Western blot analysis using a human-specific anti-
CREG antibody. We detected a robust expression of human CREG
protein in the hearts of TG mice, but not in other organs (Fig. 1A).
Among four established lines of TG mice, the line that expressed
the highest levels of the human CREG protein in the heart was
used for further experiments (Fig. 1B). Western blot analysis
 further demonstrated that the endogenous mouse CREG protein
expression was not modified by exogenous human CREG gene or
protein (Fig. 1C). To investigate whether CREG expression is
 regulated by pressure overload, WT mice were subjected to AB for
different durations. CREG expression in the left ventricle was
markedly decreased compared to basal levels after 8 weeks of AB
(Fig. 1D). Importantly, the protein  levels of TG CREG were not sig-
nificantly affected by AB and this pattern of expression  persisted
in hearts for 8 weeks after  surgery (Fig. 1D).
The effect of CREG on cardiac hypertrophy in vivo
To determine whether cardiac overexpression of CREG antago-
nized the hypertrophic response to pressure overload, WT lit-
termates and TG mice were subjected to AB surgery or sham
operation. TG mice showed significant attenuation of hypertro-
phy after 8 weeks AB compared to WT littermates, as measured
by the ratios of HW/BW, LW/BW and cardiomyocyte cross-
 sectional area (Table 1). No significant differences were observed
in the sham-operated TG and WT mice. Cardiac dilatation, wall
thickness and dysfunction were also inhibited or reversed in TG
mice, as evidenced by improvements in left ventricular end-
 systolic diameter, left ventricular end-diastolic diameter, left
ventricular posterior wall thickness, left ventricular septum,
diastolic and percent fractional shortening (%FS) (Table 1).
Gross hearts, haematoxylin and eosin and WGA staining further
confirmed the inhibitory effect of CREG on cardiac remodelling
after AB (Fig. 2A, C and D). We next examined the potential role
of CREG on hypertrophy induced by Ang II infusion. Osmotic
minipumps were implanted subcutaneously for a 4-week admin-
istration period, followed by cardiac functional assessment. 
The Ang II-induced increase in HW/BW and LW/BW as well as
J. Cell. Mol. Med. Vol 13, No 7, 2009
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cardiomyocyte cross-sectional area were also attenuated in TG
mice compared to WT mice (Table 2). Cardiac- specific overex-
pression of CREG abrogated Ang II-induced cardiac chamber
dilatation and wall thickness in both systole and diastole (Table
2). These findings were confirmed by histological analysis (Fig.
2B, E and F). Atrial natriuretic peptide (ANP), B-type natriuretic
peptide (BNP), myosin heavy polypeptide 7 cardiac muscle 
(Myh7), and actin 1 skeletal muscle (Acta1) are markers for
cardiac hypertrophy [13]. To determine whether CREG affected
the mRNA expression levels of these markers, we performed
real-time PCR. Our results showed that the induction of these
hypertrophic genes was severely blunted in TG mice in response
to AB and Ang II infusion (Fig. 2G and H). These findings sug-
gest that CREG prevents the development of cardiac hypertrophy
induced by pressure overload or Ang II stimulation in vivo.
The effect of CREG on MEK-ERK1/2 signalling
pathway
To explore the molecular mechanisms through which CREG atten-
uates the hypertrophic response, we examined the state of activa-
tion of MAPK in TG and WT hearts in the two hypertrophic mod-
els. We found that the phosphorylated levels of MEK1, ERK1/2,
p38 and JNK1/2 were significantly increased in both AB and Ang
II-infused WT hearts. However, the increased level of MEK1/2 and
ERK1/2 was almost completely blocked in TG hearts, whereas p38
and JNK1/2 were similarly activated in the WT and TG mice 
(Fig. 3A and B). Collectively, these data suggest that constitutive
expression of CREG blunts the activation of MEK-ERK1/2 sig-
nalling, although it has no effect on p38 and JNK activation in
hearts subjected to AB or Ang II stimulation.
In order to further examine the role of CREG on MEK-ERK1/2
signalling in the heart, we exposed cultured neonatal rat
 cardiomyocytes to 1 m Ang II infected with Ad-CREG or  
Ad-shCREG. At the beginning, we screened three shCREG and
found that no. 3 shCREG markedly inhibited CREG expression in
cardiac myocytes (Fig. 3C). Therefore, we chose no. 3 shCREG
for the following experiments. Further studies showed that Ang
II induced a significant phosphorylation of MEK and ERK1/2 that
was almost completely blocked and sustained for all tested time-
points by overexpression of CREG, whereas decreased CREG
levels by infection of Ad-shCREG resulted in pronounced
 activation of MEK and ERK1/2 in cardiac myocytes (Fig. 3D). Our
Table 2 Echocardiographic data showed the effects of CREG on Cardiac hypertrophy induced by Ang II infusion
*P 	 0.01 was obtained for the WT-Saline values; §P 	 0.01 was obtained for the WT-Ang II infusion values after Ang II infusion.
Parameter WT-saline mice TG-saline mice WT-Ang II mice TG-Ang II mice
Number n 
 9 n 
 10 n 
 10 n 
 9
BW, g 25.3  1.7 25.1  1.4 25.9  1.2 26.2  1.6
HW/BW 4.58  0.11 4.52  0.03 5.79  0.07* 4.85  0.04§
LW/BW 5.18  0.05 5.16  0.06 6.22  0.05* 5.29  0.07§
CSA 252  24.5 255  25.9 398  30.2* 278  21.4§
SBP, mmHg 117.2  4.7 115.9  4.8 145.2  3.7* 143.7  5.2*
HR, beats/min. 449  28 451  25 468  17 472  31
PWT(mm) 1.23  0.02 1.26  0.04 2.63  0. 03* 1.59  0.04§
LVEDD (mm) 3.65  0.03 3.67  0.04 4.74  0.05* 3.88  0.04§
LVESD (mm) 2.42  0.05 2.41  0.06 3.48  0.02* 2.52  0.03§
IVSd (mm) 0.61  0.03 0.64  0.05 1.35  0.04* 0.85  0.03§
LVPWd (mm) 0.64  0.03 0.65  0.05 1.32  0.05* 0.81  0.03§
FS (%) 55.2  3.1 54.7  2.5 37.6  1.6* 47.1  1.6*§
EF (%) 60.2  3.6 58.7  4.2 30.5  3.4* 47.5  3.1*§
LVEDP (mm Hg) 9.4  1.3 9.7  1.5 16.6  1.7* 11.9  1.6§
Left ventricular dP/dTmax (mm Hg/s) 8983.7  511.8 8879.6  477.8 7029.8  455.5* 8333.9  500.8§
Left ventricular dP/dTmin (mm Hg/s) 8115.6  431.6 8289.7  475.3 6889.7  483.2* 7884.8  458.2§
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findings suggest that CREG inhibits MEK-ERK1/2 signalling both
in vitro and in vivo in response to hypertrophic stimuli. Naturally,
we further investigated whether CREG directly interacts with
MEK-ERK signalling. Immunoprecipitation analysis showed that
CREG directly interacted with MEK1 (Fig. 3E). In order to exam-
ine whether MEK-ERK1/2 signalling has a causative role in
CREG-mediated inhibition of cardiac hypertrophy, further in vitro
experiments were performed. As expected, decreased CREG lev-
els led to pronounced hypertrophy induced by Ang II as
assessed by [H3]-leucine incorporation and surface area meas-
urements, which was strongly blunted by treatment with ERK1/2
inhibitor U0126 (Fig. 3F). These results suggest that CREG
inhibits cardiac hypertrophy through direct inhibition of MEK-
ERK1/2 signalling in cardiac myocytes.
The effect of CREG on fibrosis in vivo and in vitro
Cardiac hypertrophy is associated with increased fibrosis in the
myocardium, characterized by the over-production of extracellular
matrix proteins [13]. To determine the extent of fibrosis in the
heart, paraffin-embedded slides were stained with PSR. Marked
interstitial fibrosis was detected in the WT mice subjected to AB or
Ang II infusion by PSR staining. The extent of cardiac fibrosis in
these two hypertrophic models was, however, remarkably reduced
in TG mice (Fig. 4A–E). Subsequent analysis of mRNA expression
levels of known mediators of fibrosis including transforming
growth factor-1(Tgf1), procollagen, type I, 1 (Col11), pro-
collagen, type III, 1(Col31) and connective tissue growth factor
(Ctgf), demonstrated a blunted response in TG mice (Fig. 4F and G).
To confirm our in vivo data, we examined the effect of CREG on
collagen synthesis in isolated cardiac fibroblasts by [3H]proline
incorporation assays. Cells were serum-starved for 24 hrs in 1%
FCS after infection with Ad-CREG and Ad-shCREG, and then
treated with TGF-1 (15 ng/ml) for the indicated time. TGF-1-
stimulated [3H]-proline incorporation was attenuated by infection
with Ad-CREG and promoted by infection with Ad-shCREG 
(Fig. 4H). To further confirm the effects of CREG on collagen
 synthesis, luciferase assay demonstrated an increase of promoter
activities of COL1A2 and CTGF with CREG inhibition, and the
 converse with CREG overexpression (Fig. 4I).
The effect of CREG on TGF-/Smad signalling
TGF-1 induces collagen synthesis via activation of a number of
transcription factors, including Smads [14, 15]. To further elucidate
Fig. 3 The effect of CREG on MEK-ERK1/2 signalling pathway. (A and B)
Representative blots of MEK1/2, ERK1/2, p38 and JNK phosphorylation
and their total protein expression at 8 weeks after AB surgery or at 
4 weeks after Ang II infusion in WT and TG mice. (C) The protein expres-
sion level of CREG after infection with Ad-CREG or Ad-shCREG. Upper,
quantitative results. Bottom, Representative blots. Values are mean 
S.E.M. *P 	 0.01 for difference from Ad-GFP group values. (D)
Representative blots of MEK1/2 and ERK1/2 activation after treated with
Ang II for indicated time in different adenovirus infected primary cardiac
myocytes. The results were reproducible in three separate experiments.
(E) Immunoprecipitation analysis showed that CREG directly interacted
with MEK1. (F) The effect of CREG on the enlargement of myocytes area
and [3H]-leucine incorporation induced by Ang II after infection with ade-
novirus. Cardiac myocytes were pre-treated with 1 m U0126 or PBS
and then treated with Ang II for 48 hrs after infection with Ad-shRNA or
Ad-shCREG for 24 hrs. The results were reproducible in three separate
experiments as mean  S.E.M. *P 	 0.01 was obtained for the control
groups; §P 	 0.01 was obtained for Ad-shRNA infection group.
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the cellular mechanisms underlying the antifibrotic effects of
CREG, we assessed the regulatory role of CREG on Smad cas-
cade activation. The increased level of Smad 2 phosphorylation
and Smad 2/3 nuclear translocation was attenuated in TG mice
in response to hypertrophic stimuli (Fig. 5A and B). We then
infected cardiac fibroblasts with Ad-CREG or Ad-shCREG and
treated with TGF-1. Western blot analyses revealed significant
phosphorylation of Smad 2 and translocation of Smad 2/3 with-
out any significant alterations in the expression of Smad 2 pro-
tein after TGF-1 treatment. Ad-CREG infection, however,
almost completely suppressed Smad 2 phosphorylation as well
as Smad 2/3 nuclear translocation (Fig. 5C). Importantly, Ad-
shCREG infection enhanced TGF-1s effects. To further examine
the mechanisms involved, we used confluent cardiac fibroblasts
infected with Ad-GFP, Ad-caERK1/2, or Ad-dnERK1/2. Activation
of ERK1/2 by infection with Ad-caERK1/2 revealed a significant
increase in, whereas blocking ERK1/2 activity by Ad-dnERK1/2
infection almost completely abrogated, collagen synthesis and
COL1A2 or CTGF promoter activities in response to TGF-1 (Fig.
5D). These findings suggest that CREG blocks collagen synthe-
sis by disrupting MEK-ERK1/2-dependent TGF--Smad signalling.
The effect of CREG on inflammation 
in vivo and in vitro
Activation of inflammatory signalling pathways promotes cardiac
hypertrophy and fibrosis, whereas inhibition of inflammation can
attenuate these responses [16, 17]. We therefore examined the
expression of four representative cytokines IL-6, IL-1, MCP-1
and TNF-, after pressure overload or Ang II stimulation.
Expression of IL-6, IL-1, MCP-1 and TNF- mRNA was signifi-
cantly elevated after AB or Ang II treatment in WT mice, but not
in TG mice (Fig. 6A and B). Further studies demonstrated that 
Fig. 4 The effects of CREG on fibrosis in vivo and in vitro. (A and B)
Picrosirius red (PSR) staining on histological sections of the left ven-
tricle was performed on indicated groups 8 weeks after AB or 4 weeks
after Ang II infusion. (C and D) Representative PSR staining of micro-
scopical images of whole heart cross sections. (E) Fibrotic
areas/whole left ventricle area from histological sections was quanti-
fied using an image-analysing system. (F and G) Real-time PCR analy-
ses of Tgf1, Col11, Col31, Ctgf were performed to determine
mRNA expression levels in indicated groups. GAPDH was used as the
sample loading control. Data represent typical results of 3 different
experiments as mean  S.E.M. (n 
 4 to 6 mice/per group). *P 	
0.01 was obtained for the WT/sham or WT/saline values. (H and I)
CREG was shown to inhibit TGF-1-induced [3H] proline incorporation
and the promoter activities of COL1A2 and CTGF. [3H] proline incor-
poration and luciferase assay were performed as described in
‘Materials and methods’. Values are mean  S.E.M. The results were
reproducible in three separate experiments. *P 	 0.01 was obtained
for  Ad-GFP infection group.
Fig. 5. The effect of CREG on TGF-
/Smad signalling. (A and B)
Representative blots of Smad-2 phos-
phorylation and Smad-2/3 transloca-
tion from indicated groups 8 weeks
after AB (n 
 3) or 4 weeks of Ang II
infusion (n 
 4). The results were
reproducible in three separate experi-
ments (CE, cytoplasmic extract; NE,
nuclear extract). (C) Representative
blots of Smad-2 phosphorylation and
Smad-2/3 translocation induced by
TGF-1 in cardiac fibroblasts after
infection with different adenovirus. (D)
The effect of ERK1/2 activation on col-
lagen synthesis along with promoter
activities of COL1A2 and CTGF. Cells
were infected with or without indicated
adenovirus for 24 hrs, and then incu-
bated with 15 ng/ml TGF-1 for up to
48 hrs. [3H] proline incorporation and
luciferase assay were performed as
described in ‘Materials and methods’.
*P 	 0.01 was obtained for control
group. The results were reproducible in
three separate experiments.
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8 weeks of AB or 4 weeks of Ang II stimulation increased the
phosphorylation of IB and IKK- in the myocardium of WT
mice, but not in TG mice (Fig. 6C). To further validate the effects
of CREG on NF-B signalling, we cultured neonatal rat cardiac
myocytes for in vitro analyses to substantiate our in vivo findings.
Inhibition of CREG promoted the induction of NF-B activity,
while overexpression of CREG attenuated these effects induced
by Ang II (Fig. 6D). These results indicate that CREG blocks 
NF-B activity and NF-B-dependent inflammatory responses in
response to hypertrophic stimuli both in vivo and in vitro. The
potential regulation of NF-B by MAPK signalling prompted us to
investigate the functional  significance of ERK1/2 on NF-B acti-
vation in response to hypertrophic stimuli. Infection of cardiac
myocytes with Ad-caERK1/2 promoted NF-B activation, whereas
infection of Ad-dn-ERK1/2 significantly attenuated NF-B activa-
tion (Fig. 6D). These results indicate that CREG blocks NF-B 
signalling and NF-B-dependent inflammatory responses partly
through disruption of MEK-ERK1/2 signalling.
Discussion
In the present study, we examined the role of CREG in cardiac
hypertrophy by using cardiac-specific CREG TG mice. The results
demonstrated that elevated levels of CREG protein expression in
TG mice profoundly blunt cardiac hypertrophy, chamber dilatation,
fibrosis and inflammation via disruption of MEK-ERK1/2 signalling
following chronic pressure overload or Ang II stimulation.
The mechanism by which CREG mediates its anti-hyper-
trophic effects remains unclear. Recent studies demonstrated
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that MAPK signalling pathways play a key role in the progress
of cardiac hypertrophy [18, 19]. The MAPK cascade consists of
a sequence of successively acting kinases, including p38, JNKs,
and ERKs and is initiated in cardiac myocytes by stress stimuli
[18, 19]. Once activated, p38, JNKs, and ERKs phosphorylate a
wide array of intracellular targets, which include numerous
 transcription factors resulting in the reprogramming of cardiac
gene expression. The role that MEK1-ERK1/2 plays in the
 regulation of cardiac hypertrophy is an area of ongoing debate
[20, 21]. It has been shown that ERK1/2 is activated in cultured
neonatal rat cardiomyocytes by agonist stimulation. Activation
of MEK1 augmented cardiac hypertrophy in cultured cardiomy-
ocytes while blocking MEK1 attenuated it. Similarly, using the
MEK1 inhibitor, U0126, demonstrated that ERKs were required
for the hypertrophic response induced by Ang II and ET-1.
However, a number of additional studies have disputed the
importance of MEK1-ERK1/2 in the regulation of cardiac
 hypertrophy, and one study has suggested that ERK activation
 prevents cardiac hypertrophy. To examine the molecular mech-
anisms involved in CREG’s ability to protect against cardiac
hypertrophy, we examined the status of MAPKs signalling in our
hypertrophic models. An important finding of this study is that
MEK and ERK1/2 activation were almost completely blocked by
cardiac expression of human CREG in response to hypertrophic
stimuli. However, the phosphorylation of p38, JNK1/2, and Akt
was not affected by CREG. Therefore MEK-ERK1/2 signalling
was a critical pathway through which CREG influences cardiac
growth. Further study demonstrated that CREG can bind directly
Fig. 6 The effect of CREG on inflamma-
tion in vivo and in vitro. (A and B) Real-
time PCR analysis of TNF-, IL-1, 
IL-6 and MCP-1 mRNA expression in
the myocardium obtained from indi-
cated groups at 8 weeks AB (A, n 
 4)
or 4 weeks Ang II infusion (B, n 
 6).
Each assay was performed in triplicate.
*P 	 0.05 for difference from
WT/sham values or WT/saline values.
(C) Western blot analysis of IB and
IKK- phosphorylation of the
myocardium was obtained from indi-
cated animals at 8 weeks AB (A, n
 5)
or 4 weeks Ang II infusion (B, n 
 4).
(D) The effects of CREG expression and
ERK1/2 activation on Ang II-induced
NF-B transcriptional activity.
Luciferase assay were performed as
described in ‘Materials and methods’.
Values are mean   S.E.M. * P	 0.01
was obtained for PBS/control group.
The results were reproducible in three
separate experiments.
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to MEK1, disrupt its interactions, and finally block its activation.
These findings are consistent with two recent studies showing
that CREG inhibits ERK1/2 activation in cardiac myocytes and
vascular muscle cells [10, 11]. Therefore, inhibition of MEK-
ERK1/2 signalling in the context of the adult heart under stress,
such as pressure overload, may provide a therapeutic strategy
to regress cardiac hypertrophy, and our data indicated that the
inhibitory effects of CREG on cardiac hypertrophy are mediated
through MEK-ERK1/2 signalling.
Pathological cardiac hypertrophy is accompanied by interstitial
and perivascular fibrosis and approaches to prevent collagen 
deposition in the heart have been limited to date [22–26]. This study
revealed that CREG blocks cardiac fibrosis in vivo and inhibits
collagen synthesis in vitro. Our study is the first to report inhibi-
tion of fibrosis and TGF-1-induced collagen synthesis in cardiac
fibroblasts by CREG. In an attempt to elucidate the mechanisms
underlying the inhibitory effect of CREG on fibrosis, we analysed
key components of TGF-1-Smad signal transduction. Blockade of
this signalling pathway was predicted to blunt fibrosis [14, 15]. In
line with these notions, our data suggest, for the first time, that
CREG abrogates Smad 2 phosphorylation and Smad 2/3 translo-
cation in both cultured cardiac fibroblasts and hypertrophied
hearts thus inhibiting collagen synthesis and fibrosis. Recent
studies indicate that TGF-1/Smad signalling can be regulated 
by MEK-ERK1/2 signalling [26]. We therefore examined the effects
of MEK-ERK1/2 activation on fibrotic signalling and found that
blocking MEK-ERK1/2 activation led to significant inhibition, while
activation of MEK-ERK1/2 resulted in up-regulation of collagen
synthesis and Smad 2/3 signalling, indicating that CREG attenu-
ates fibrosis by blocking MEK-ERK1/2 signalling.
Cardiac hypertrophy and fibrosis may be promoted by acti-
vation of inflammatory signalling pathways [27–30]. We
observed that the induction of inflammatory cytokines by hyper-
trophic stimuli was attenuated by cardiac-forced expression of
CREG, indicating an important role for CREG in regulating
inflammatory response in the heart. One possible mechanism
for such a protective effect is that CREG expression directly
blocks NF-B activation, resulting in attenuation of downstream
cytokines, including IL-1, TNF-, IL-6 and MCP-1, each of
which has a B-binding domain in its promoter site. Our pres-
ent data suggest that CREG abrogates NF-B activation by dis-
rupting DNA binding and the phosphorylation of IB. By block-
ing NF-B signalling, CREG may inhibit the early steps of
inflammation and modulate the amplification of multiple
cytokine signalling cascades. Therefore, treatment of targeting
NF-B may be a more attractive approach to blocking each
respective cytokine individually.
In conclusion, for the first time, we identified the role of CREG
in maintaining cardiac contractility and reducing fibrosis and
inflammation in response to hypertrophic stimuli both in vitro and
in vivo. The sub-cellular mechanism underlying the protective role
of CREG against cardiac hypertrophy has been shown to be via
inhibiting the MEK-ERK1/2 signalling pathway. Our study provides
insights into the mechanisms of cardiac hypertrophy and may be
of great value for developing novel treatment strategies for cardiac
hypertrophy through targeting CREG signalling pathway.
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